Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia

SUMMIT, N.J.& CAMBRIDGE, Mass.June 04, 2019 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news